Acute Calcium Disorders

[1]  C. M. Haring,et al.  Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia , 2007, Clinical endocrinology.

[2]  R. Smallridge,et al.  Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[3]  E. Schwarz,et al.  Clinical development of anti-RANKL therapy , 2007, Arthritis research & therapy.

[4]  R. Dickerson.  Treatment of hypocalcemia in critical illness--part 1. , 2007, Nutrition.

[5]  E. Eriksen,et al.  Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. , 2007, Critical reviews in oncology/hematology.

[6]  R. Bouillon,et al.  Duodenal calcium absorption in dexamethasone-treated mice: functional and molecular aspects. , 2007, Archives of biochemistry and biophysics.

[7]  R. Dickerson.  Treatment of hypocalcemia in critical illness--part 2. , 2007, Nutrition.

[8]  M. Hediger,et al.  Marked Disturbance of Calcium Homeostasis in Mice With Targeted Disruption of the Trpv6 Calcium Channel Gene , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. Hoenderop,et al.  Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[10]  S. Sheen-Chen,et al.  Skin Necrosis After Intravenous Calcium Chloride Administration as a Complication of Parathyroidectomy for Secondary Hyperparathyroidism: Report of Four Cases , 2007, Surgery Today.

[11]  W. Dougall,et al.  The RANK/RANKL/OPG triad in cancer-induced bone diseases , 2007, Cancer and Metastasis Reviews.

[12]  Roland Baron,et al.  Molecular regulation of osteoclast activity , 2007, Reviews in Endocrine and Metabolic Disorders.

[13]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[14]  D. Herold,et al.  Causes of hypercalcemia in a population of military veterans in the United States. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[15]  S. Silverberg,et al.  The diagnosis and management of asymptomatic primary hyperparathyroidism , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[16]  M. Malaguarnera,et al.  The management of tumor lysis syndrome , 2006, Nature Clinical Practice Oncology.

[17]  R. Schrier.  Body water homeostasis: clinical disorders of urinary dilution and concentration. , 2006, Journal of the American Society of Nephrology : JASN.

[18]  P. Stiff,et al.  Management of the adverse effects associated with intravenous bisphosphonates. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Schold,et al.  Improvement in hypercalcemia with cinacalcet after kidney transplantation. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[20]  J. Hoenderop,et al.  Coordinated control of renal Ca2+ handling. , 2006, Kidney international.

[21]  M. Dantas,et al.  Acute Renal Failure and Hypercalcemia , 2006, Renal failure.

[22]  S. Ruggiero,et al.  Bisphosphonate complications including osteonecrosis of the jaw. , 2006, Hematology. American Society of Hematology. Education Program.

[23]  I. Modlin,et al.  The molecular genetics of gastroenteropancreatic neuroendocrine tumors , 2005, Cancer.

[24]  C. Mathieu,et al.  Immune Regulation of 25‐Hydroxyvitamin‐D3‐1α‐Hydroxylase in Human Monocytes , 2005 .

[25]  W. Yeh,et al.  IMPLICATION OF TOLL-LIKE RECEPTOR AND TUMOR NECROSIS FACTOR α SIGNALING IN SEPTIC SHOCK , 2005 .

[26]  L. Duck,et al.  Osteonecrosis of the jaw and bisphosphonates. , 2005, The New England journal of medicine.

[27]  H. Jüppner,et al.  Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. , 2005, Biochemical and biophysical research communications.

[28]  P. Shanthi,et al.  Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage , 2005, Journal of Bone and Mineral Metabolism.

[29]  Q. Duh,et al.  Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. , 2004, Archives of surgery.

[30]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[31]  J. Berry,et al.  Biphasic hypercalcemia in severe rhabdomyolysis: serial analysis of PTH and vitamin D metabolites. A case report and literature review. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  R. Marcus.  Diagnosis and Treatment of Hyperparathyroidism , 2000, Reviews in Endocrine and Metabolic Disorders.

[33]  F. Singer,et al.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy , 1992, Calcified Tissue International.

[34]  J. Bilezikian,et al.  The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. , 2003, The Journal of clinical endocrinology and metabolism.

[35]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[36]  W. Goodman,et al.  Medical management of secondary hyperparathyroidism in chronic renal failure. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  P. V. D. van der Voort,et al.  Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill , 2003, Critical care medicine.

[38]  B. Leyland-Jones.  Treatment of cancer-related hypercalcemia: the role of gallium nitrate. , 2003, Seminars in oncology.

[39]  G. Van den Berghe,et al.  Bone turnover in prolonged critical illness: effect of vitamin D , 2003, The Journal of clinical endocrinology and metabolism.

[40]  M. Stockler,et al.  Bisphosphonates for breast cancer. , 2005, The Cochrane database of systematic reviews.

[41]  F. Locatelli,et al.  Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  J. Warren,et al.  Rhabdomyolysis: A review , 2002, Muscle & nerve.

[43]  P. Carmeliet,et al.  Duodenal calcium absorption in vitamin D receptor–knockout mice: Functional and molecular aspects , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Mills,et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  O. Sharma.  Hypercalcemia in granulomatous disorders: a clinical review. , 2000, Current opinion in pulmonary medicine.

[46]  S. Rabbani,et al.  Molecular basis of the spectrum of skeletal complications of neoplasia , 2000, Cancer.

[47]  T. Gerber,et al.  Digoxin, hypercalcaemia, and cardiac conduction , 1999, Postgraduate medical journal.

[48]  G. Romieu,et al.  A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer Patients , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[49]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[50]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[51]  A. Stoll,et al.  Alterations in parathyroid dynamics in lithium-treated subjects. , 1997, The Journal of clinical endocrinology and metabolism.

[52]  D. Jeon,et al.  Calcium-free hemodialysis for the management of hypercalcemia. , 1996, Nephron.

[53]  J. S. Marks,et al.  Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate , 1995, Clinical endocrinology.

[54]  Marybeth Brown.  Book Review Post-Polio Syndrome Edited by Lauro S. Halstead and Gunnar Grimby. 230 pp. St. Louis, Mosby, 1995. $32.95. 1-56053-117-7 , 1995 .

[55]  J. Seidman,et al.  Calcium-ion-sensing cell-surface receptors. , 1995, The New England journal of medicine.

[56]  M. Davies.  Hyperparathyroidism in X‐linked hypophosphataemic osteomalacia , 1995, Clinical endocrinology.

[57]  E. Brown,et al.  Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. , 1994, The Journal of clinical investigation.

[58]  J. Bilezikian.  Clinical review 51: Management of hypercalcemia. , 1993, The Journal of clinical endocrinology and metabolism.

[59]  I. Henderson,et al.  Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. , 1993, The American journal of medicine.

[60]  T. Martin,et al.  Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia , 1993, The Lancet.

[61]  A. F. Stewart,et al.  Intraperitoneal free fatty acids induce severe hypocalcemia in rats: A model for the hypocalcemia of pancreatitis , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  D. Heath.  Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management. , 1989, Endocrinology and metabolism clinics of North America.

[63]  S. Massry,et al.  Hypocalcemia and hypercalcemia in patients with rhabdomyolysis with and without acute renal failure. , 1986, The Journal of clinical endocrinology and metabolism.

[64]  D. Gann,et al.  Hypercalcemia in Critically Ill Surgical Patients , 1985, Annals of surgery.

[65]  J. Kanis,et al.  Role of glucocorticoids in management of malignant hypercalcaemia. , 1984, British medical journal.

[66]  D. Hosking,et al.  Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. , 1984, The Quarterly journal of medicine.

[67]  T. Clemens,et al.  Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. , 1984, The Quarterly journal of medicine.

[68]  A. F. Stewart,et al.  Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. , 1982, The New England journal of medicine.

[69]  W. Suki.  Effects of diuretics on calcium metabolism. , 1982, Advances in experimental medicine and biology.

[70]  D. Hosking,et al.  Rehydration in the treatment of severe hypercalcaemia. , 1981, The Quarterly journal of medicine.

[71]  A. F. Stewart,et al.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. , 1980, The New England journal of medicine.

[72]  C. Cardella,et al.  Role of dialysis in the treatment of severe hypercalcemia: report of two cases successfully treated with hemodialysis and review of the literature. , 1979, Clinical nephrology.

[73]  L. Drop,et al.  Low Plasma Ionized Calcium and Response to Calcium Therapy in Critically Ill Man , 1975, Anesthesiology.

[74]  J. Wolter,et al.  Mithramycin treatment of hypercalcemia , 1970, Cancer.

[75]  O. Khoo,et al.  Intracellular magnesium depletion in chronic renal failure. , 1969, The New England journal of medicine.

[76]  M. Walser.  Ion association. VI. Interactions between calcium, magnesium, inorganic phosphate, citrate and protein in normal human plasma. , 1961, The Journal of clinical investigation.